Last reviewed · How we verify
NCT03633630
Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Phase 2, PHASE3 trial testing Amla in Metabolic Syndrome in 28 participants. Completed in 30 March 2022.
30 October 2021
Quick facts
| Lead sponsor | University of Guadalajara |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 1 April 2019 |
| Primary completion | 30 October 2021 |
| Estimated completion | 30 March 2022 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Amla — full drug profile →
- Placebo
Conditions studied
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
Sponsor
University of Guadalajara
Who can join
Adults 30 to 59, any sex, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Amla has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Amla has an excellent potential for the prevention and treatment of metabolic syndrome.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Molecular Mechanisms of Cancer Prevention by Gooseberry (<i>Phyllanthus emblica</i>).
Kumar G, Madka V, Pathuri G, Ganta V, et al · · 2022 · cited 14× · PMID 34839775 · DOI 10.1080/01635581.2021.2008988
Verify or expand the search:
- PubMed search for NCT03633630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Syndrome
Currently open trials in the same condition.
- NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
- NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
- NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
Other University of Guadalajara trials
Trials by the same sponsor.
- NCT06915701 — "Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis" · Phase 2, PHASE3 · recruiting
- NCT07487623 — Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chron · NA · recruiting
- NCT07056712 — Effect of Fenugreek Seed Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion · NA · not yet recruiting
- NCT07408947 — Clinical Severity in Scorpion Envenomation: Home Remedies, Delay to Medical Care, and Antivenom Dosing Strategies in an · completed
- NCT06829186 — The Effect of Curcumin on Inflammatory Markers in Hemodialysis Patients · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03633630 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Guadalajara
- Last refreshed: 8 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03633630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing